Vitreous Opacity
Conditions
Interventions
Control Group:Zhangyanming Tablets Placebo
Sponsors
Shanghai First People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for physiological vitreous opacities; 2. Identified by traditional Chinese medicine as having liver and kidney yin deficiency syndrome; 3. Floaters symptoms persist for more than 2 months; 4. Age between 40 and 70 years old (inclusive), gender; 5. Intraocular pressure: 10~21 mmHg; 6. No use of related treatment medications within the past month, with good compliance; 7. Voluntarily sign the informed consent form and be able to cooperate with follow-up and examinations.
Exclusion criteria
Exclusion criteria: 1. Presence of pathological vitreous opacities-related diseases, such as: (1) Retinal tear, retinal detachment; (2) Vitreous hemorrhage; (3) Uveitis, retinitis, choroiditis, etc., inflammatory diseases; (4) Diabetic retinopathy, hypertensive retinopathy, etc., vascular lesions; (5) History of ocular trauma; (6) Previous ocular surgery history: such as cataract surgery, vitrectomy, retinal laser photocoagulation, etc.; (7) High myopia (> -6.00D) combined with fundus lesions; (8) Vitreous degeneration, liquefaction, or pathological posterior vitreous detachment (PVD); (9) Lens dislocation, intraocular tumors, congenital ocular abnormalities, etc., organic lesions; 2. Patients with hyperthyroidism, hypotension, and endocrine disorders; 3. Patients with severe cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic system diseases (ALT, AST = 1.5 times the upper limit of normal, SCr > upper limit of normal); 4. Pregnant or breastfeeding women, or those with neurological or psychiatric conditions who are unable or unwilling to cooperate; 5. Known or suspected history of allergy to the investigational drug or its excipients, severe adverse reactions, or allergic constitution; 6. Participants who have enrolled in other clinical trials within the past 3 months; 7. Other situations deemed unsuitable for participation in this trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative Ultrasound Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Best corrected distance visual acuity;Contrast Sensitivity;Intraocular pressure;Visual Function Assessment Scale;TCM Syndrome Score; | — |
Countries
China
Contacts
Public ContactLiu Kun
Shanghai First People's Hospital
Outcome results
None listed